{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-186747","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2024-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.230392+00:00","generated_at":"2026-05-31T15:48:13.278053+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NAMS: Phase 3 BROOKLYN trial of obicetrapib meets primary endpoint; LDL-C down 36.3% at day 84","bullets":["LDL-C reduced 36.3% vs placebo at day 84 and 41.5% at day 365, both p<0.0001.","51% of patients on obicetrapib achieved LDL-C below 70 mg/dL.","Safety comparable to placebo; TEAEs 63.7% vs 70.3%, discontinuation 7.6% vs 14.4%.","Mean baseline LDL-C was 123 mg/dL despite 79% on high-intensity statins.","Next data readouts: BROADWAY (Q4 2024) and TANDEM (Q1 2025)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-186747","json":"https://secwatch.observer/filing/0001193125-24-186747.json","markdown":"https://secwatch.observer/filing/0001193125-24-186747.md","text":"https://secwatch.observer/filing/0001193125-24-186747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524186747/0001193125-24-186747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312524186747/d660026d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:48:13.278053+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}